Growth Hormone Deficiency Market Set for Significant Growth, Driven by Leading Brands and Expanding Applications

AUSTIN, TX, UNITED STATES, March 3, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The Growth Hormone Deficiency Market was valued at USD 5.4 billion in 2023 and is projected to reach USD 8.5 billion by 2032, expanding at a CAGR of 5.0% from 2024 to 2032. The market growth is fueled by advancements in recombinant human growth hormone therapies, growing awareness about pediatric growth disorders, and improved access to treatment options.

Key Players in Growth Hormone Deficiency Market
• Eli Lilly and Company
• ROCHE (Genentech Inc.)
• Ferring B.V
• Pfizer Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd
• Novartis AG
• Merck Kga
• Anhui Anke Biotechnology Group Co. Ltd
• EMD Serono Inc

Get a Free Sample Report@ https://www.snsinsider.com/sample-request/2654

Segmentation Analysis

By Brand, Norditropin, manufactured by Novo Nordisk, emerged as the dominant brand in the GHD market in 2023, holding the largest share valued at USD 1.6 billion.

Its well-proven effectiveness, extensive availability, and regular usage by healthcare practitioners have been contributing factors in ensuring its leadership role. The continuous research and development efforts of the brand, as well as its convenience of administration through prefilled injection devices, have further consolidated its market leadership.

The most rapidly growing brand in the GHD segment is likely to be Genotropin. The increasing demand for customized and convenient treatment alternatives, coupled with growing patient inclination towards pen-device drug delivery systems, has been a key driver of its growth. Advances in drug formulations and targeted marketing campaigns are likely to fuel its growth path in the future.

By Application, Idiopathic Short Stature (ISS) held the largest share of the GHD market in 2023, accounting for 45% of the total market and generating USD 2.5 billion in revenue.

The widespread use of growth hormone therapy among children, spurred by early detection and parental education, has been at the forefront in making this market the largest. In addition, approvals that favored the use of growth hormone for ISS cases have also spurred the demand for such therapies.

On the other hand, the fastest-growing application sector is Adult Growth Hormone Deficiency (AGHD). The increasing recognition of GHD's impact on adult health, such as reduced bone density, metabolic abnormalities, and cardiovascular risk, has spurred demand for effective therapies. Advanced diagnostic methods and introduction of patient-centered treatment strategies will most likely propel the growth of this segment.

By End-User, Hospital pharmacies accounted for the largest share of the GHD market in 2023, holding a 48% share and generating USD 2.7 billion in revenue.

These organizations are major distribution points for growth hormone treatments, guaranteeing consistent patient access to ordered therapies. The availability of skilled healthcare professionals and strict medication management practices in hospitals also helps contribute to the prevalence of this segment.

In contrast, online pharmacies are the most rapidly growing end-user segment. The ease of home delivery, growth in digital adoption in the health space, and value-based pricing strategies have accelerated the growth of online pharmaceutical platforms. Further, the growth of e-prescription services and telemedicine consultations has greatly benefited the increasing adoption of online pharmacy services for growth hormone treatment.

Speak with Our Expert Analyst Today to Gain Deeper Insights @ https://www.snsinsider.com/request-analyst/2654

Regional Analysis

North America dominated the GHD market in 2023, accounting for a 40% market share and contributing USD 2.2 billion in revenue.

The dominance in the region is due to the high incidence rates of growth hormone disorders, developed healthcare infrastructure, and good support from insurance payors for hormone replacement therapies. Furthermore, the availability of major drug companies and intensive research activities further established North America as the dominant market region.

While this, the Asia-Pacific market will be the region's fastest-growing for GHD treatment. Growth in healthcare investment, growing awareness of pediatric and adult GHD, and enhancing access to newer therapies are propelling market growth. China, India, and Japan are all seeing a spike in demand for recombinant human growth hormone therapies, driven by changing regulatory environments and rising affordability of treatment. With the region further developing its healthcare infrastructure, it is set for strong growth in the years to come.

Buy Full Research Report on Growth Hormone Deficiency Market 2024-2032 @ https://www.snsinsider.com/checkout/2654

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave
SNS Insider Pvt. Ltd
+1 315 636 4242
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.